



## **Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2008**

July 26, 2007

### **-- Podcast to be Available Following Conference Call --**

CAMBRIDGE, Mass., Jul 26, 2007

(BUSINESS WIRE) -- Alkermes, Inc. (Nasdaq: ALKS) will host a conference call at 4:30 p.m. EDT on Thursday, August 2, 2007 to discuss the company's financial results for its first quarter of fiscal 2008. Management will review the quarter and provide an update on the company.

The conference call will be webcast on the investor relations section of Alkermes' website at [www.alkermes.com](http://www.alkermes.com) or may be accessed by dialing 1-866-835-8825 for domestic callers and 1-703-639-1407 for international callers. The conference call ID number is 1119053.

A replay of the conference call will be available from 7:30 p.m. EDT on Thursday, August 2, 2007 through 5:00 p.m. EDT on Tuesday, August 7, 2007, and may be accessed by visiting Alkermes' website or by dialing 1-888-266-2081 for domestic callers and 1-703-925-2533 for international callers. The replay access code is 1119053. Alkermes is also providing a podcast MP3 file available for download on the Alkermes website, which will be available shortly following the conference call and will be available until Tuesday, August 7, 2007.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL(R) CONSTA(R) ((risperidone) long-acting injection), the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag (Janssen), a wholly owned division of Johnson & Johnson; and VIVITROL(R) (naltrexone for extended-release injectable suspension) the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes. Alkermes' headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

SOURCE: Alkermes, Inc.

Alkermes, Inc.

Debra Koufos, 617-583-6220

Associate, Corporate Communications